|Other Names||AF4/FMR2 family member 1, ALL1-fused gene from chromosome 4 protein, Protein AF-4, Protein FEL, Proto-oncogene AF4, AFF1, AF4, FEL, MLLT2, PBM1|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP6189a was selected from the C-term region of human MLLT2 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Synonyms||AF4, FEL, MLLT2, PBM1|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
MLLT2 is involved in acute leukemias through a chromosomal translocation t(4;11)(q21;q23) that involves mllt2 and mll/hrx. AF-4 (MLLT2), AF-9, and ENL proteins contain nuclear targeting sequences as well as serine-rich and proline-rich regions. Stretches abundant in basic amino acids are also present in the three proteins. These results suggest that the different proteins fused to ALL-1 polypeptide(s) provide similar functional domains. AF4 is a serine- and proline-rich putative transcription factor with a glutamine-rich carboxyl terminus. The composition of the complete MLL-AF4 fusion product argues that it may act through either a gain-of-function or a dominant negative mechanism in leukemogenesis.
Domer, P.H., et al., Proc. Natl. Acad. Sci. U.S.A. 90(16):7884-7888 (1993).Nakamura, T., et al., Proc. Natl. Acad. Sci. U.S.A. 90(10):4631-4635 (1993).Morrissey, J., et al., Blood 81(5):1124-1131 (1993).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.